Alla studier
RekryteringFAS1, FAS2INTERVENTIONELL

En studie för att utvärdera säkerheten och effekten av AVB-101, en genterapiprodukt, hos personer med en genetisk subtyp av frontotemporal demens (FTD-GRN)

This research is looking into a new gene therapy called AVB-101 for a specific type of dementia called Frontotemporal Dementia with Progranulin Mutations (FTD-GRN). This condition affects younger people and leads to problems with a brain protein called progranulin. The study wants to find out if AVB-101 is safe, can restore this protein to normal levels, and potentially slow down the disease. All participants will receive a one-off treatment delivered directly to the brain, and doctors will monitor them for five years. The study involves people aged 30 to 75 who have FTD-GRN and meet specific health requirements.

Överblick

Status
Rekrytering
Fas
FAS1, FAS2
Sponsor
AviadoBio Ltd
Inskrivningsmål
18
Starta
30 aug 2023
Beräknad slutförande
21 Mar 2030

Vad handlar denna studie om?

This study is looking into a new treatment for a specific type of dementia called Frontotemporal Dementia with Progranulin Mutations, or FTD-GRN. FTD is a brain condition that gets worse over time and can affect a person's behaviour, speech, and movement.

In FTD-GRN, these problems happen because there isn't enough of a vital protein called progranulin in the brain. This lack of protein causes brain cells to die, which then affects how the brain works. The new treatment, called AVB-101, is a type of 'gene therapy'. This means it's designed to help the body make more of the missing progranulin protein.

The main goals of this study are to: 1) check if AVB-101 is safe for people with FTD-GRN, 2) see if it can bring progranulin levels back to normal in the brain, and 3) explore if it can help slow down or even stop the disease from getting worse. This is an early-stage study, meaning it's one of the first times this treatment is being tested in people.

Viktiga punkter

  • This study is for people with a specific type of Frontotemporal Dementia called FTD-GRN.
  • It's testing a new gene therapy, AVB-101, to see if it's safe and can help raise progranulin levels.
  • Participants will receive a one-time treatment delivered directly into the brain.
  • The study lasts for five years after the treatment.
  • There's no placebo; everyone gets the active treatment.
  • It's an early-stage study, so the full effects and risks are still being learned.

Vem kan vara berättigad?

The study is looking for both men and women between the ages of 30 and 75. To be considered, you must have been diagnosed with Frontotemporal Dementia due to a specific genetic change (a GRN mutation).

Doctors will also check how your dementia is affecting you, looking for certain signs related to changes in behaviour or language. You must also be able to follow all the study instructions and attend appointments, and you'll need to have a chosen study partner who can help support you and provide information during the study.

There are also some reasons why you might not be able to join. For example, if your dementia is very severe, or if you have other health conditions that could affect your brain or make the treatment unsafe. You also can't have had certain other experimental treatments or gene therapies before.

Kan denna studie passa dig?

Svara på dessa snabba frågor för att se om du kan vara berättigad. Detta är endast en vägledning — forskarteamet fattar det slutgiltiga beslutet.

  1. Are you between 30 and 75 years old?
  2. Have you been diagnosed with Frontotemporal Dementia caused by a GRN gene mutation?
  3. Are you able and willing to attend all study visits and follow instructions?
  4. Do you have a family member or friend who can be your 'study partner'?
  5. Do you have any other serious health conditions that might prevent you from joining?
  6. Have you had any other gene therapy or similar experimental treatments before?
Svara på varje fråga för att se ditt resultat.

Vad innebär deltagande?

If you join this study, you won't receive a 'dummy' treatment; everyone will receive the actual study treatment, AVB-101. This treatment is given just once, directly into the brain through a procedure. After this single treatment, doctors will closely monitor your health and how you're responding for a period of five years. This will involve regular check-ups, tests, and assessments to see how you are doing.

Potentiella risker och fördelar

Participating in research studies like this can have potential benefits, such as gaining access to a new, experimental treatment that might help with your condition, and contributing to medical knowledge benefiting others. However, there are also potential risks involved, including those related to the procedure to deliver the treatment, and possible side effects from AVB-101 itself, which are not yet fully known. It's very important to remember that you have the right to withdraw from the study at any time, for any reason, without it affecting your usual medical care.

Platser (19)

  • The Ohio State University (OSU) Wexner Medical Center
    Verifierat postnummer
    Columbus, USA· Rekrytering
  • Vanderbilt University Medical Centre
    Verifierat postnummer
    Nashville, USA· Rekrytering
  • Houston Methodist Hospital
    Verifierat postnummer
    Houston, USA· Rekrytering
  • UZ Leuven
    Verifierat postnummer
    Leuven, Belgien· Rekrytering
  • Sunnybrook Health Sciences Centre
    Verifierat postnummer
    Toronto, Kanada· Rekrytering
  • Fondazione IRCCS Istituto Neurologico Carlo Besta
    Verifierat postnummer
    Milano, Italien· Rekrytering
  • Amsterdam UMC
    Verifierat postnummer
    Amsterdam, Nederländerna· Rekrytering
  • NEURO-CARE Sp. z o.o. Sp. Komandytowa
    Verifierat postnummer
    Katowice, Poland· Rekrytering
  • Neurologia Slaska Centrum Medyczne
    Verifierat postnummer
    Katowice, Poland· Rekrytering
  • Uniwersyteckie Centrum Kliniczne, SUM w Katowicach
    Verifierat postnummer
    Katowice, Poland· Rekrytering
  • Euromedis Sp. z o.o.
    Verifierat postnummer
    Szczecin, Poland· Rekrytering
  • Centrum Medyczne NeuroProtect Sp z o.o.
    Verifierat postnummer
    Warszawa, Polen· Rekrytering

Vanliga frågor

What is FTD-GRN?

FTD-GRN is a type of Frontotemporal Dementia caused by a change in a specific gene, leading to low levels of a protein called progranulin in the brain.

Vad är genterapi?

Gene therapy is a new kind of treatment that aims to correct problems with genes to help the body work correctly, in this case, by hopefully increasing progranulin protein levels.

Is AVB-101 a cure for FTD-GRN?

AVB-101 is an experimental treatment being studied to see if it can help treat FTD-GRN, but it is not yet known if it can cure the condition.

Will I get a placebo in this study?

No, there is no placebo in this study. All participants will receive the active study treatment, AVB-101.

Hur länge kommer jag att vara involverad i studien?

After receiving the one-time treatment, you will be monitored by the study team for five years.

Hur du får reda på mer

AviadoBio Clinical Trials

Prata alltid med din läkare eller specialist innan du bestämmer dig för att delta i en studie.

Intresserad av att delta?

Registrera ditt intresse

Dela dina uppgifter och forskarteamet för "A Study to Evaluate the Safety and Effect of AVB-101, a Gene…" kommer att kontakta dig om du kan vara berättigad. Prata alltid med din läkare innan du går med på att delta.

Diskussion

Gemenskapsdiskussion

Drivs av vårt forum på community.patient.info. Var vänlig och respektfull — detta är inte medicinsk rådgivning.